pbs  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Name:
    Influenza A H1N1 A California 07 2009 Matrix protein 1 M1 Gene ORF cDNA clone expression plasmid Codon Optimized
    Description:
    Full length Clone DNA of Influenza A H1N1 A California 07 2009 Matrix protein 1 M1
    Catalog Number:
    VG40212-UT
    Price:
    295.0
    Category:
    cDNA Clone
    Applications:
    Stable or Transient mammalian expression
    Size:
    1Unit
    Molecule Name:
    M1,M1R,Matrix protein 1
    Buy from Supplier


    Structured Review

    Sino Biological pbs
    Influenza A H1N1 A California 07 2009 Matrix protein 1 M1 Gene ORF cDNA clone expression plasmid Codon Optimized
    Full length Clone DNA of Influenza A H1N1 A California 07 2009 Matrix protein 1 M1
    https://www.bioz.com/result/pbs/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pbs - by Bioz Stars, 2021-07
    90/100 stars

    Images

    1) Product Images from "Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk"

    Article Title: Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0114361

    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).
    Figure Legend Snippet: Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Techniques Used: Recombinant, Enzyme-linked Immunosorbent Assay

    2) Product Images from "Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk"

    Article Title: Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0114361

    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).
    Figure Legend Snippet: Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Techniques Used: Recombinant, Enzyme-linked Immunosorbent Assay

    Related Articles

    Sequencing:

    Article Title: Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
    Article Snippet: The cOVA coding sequence was amplified by PCR from the vector pCI-neo-cOVA , (a gift from Maria Castro, University of California, Los Angeles; Addgene plasmid no. 25097), and was cloned into pcDNA3, pTK126, or pSFV1-JC1 using the In-Fusion cloning kit according to the manufacturer’s instructions. .. The influenza HA coding sequence was amplified from the commercially available expression-ready influenza A H1N1 (A/WSN/33) cDNA clone, codon-optimized, full-length ORF (product no. VG11692-C; Sino Biological). .. EBOV GP coding sequences were amplified from pWRG7077-GP.

    Article Title: Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
    Article Snippet: Cells were then fixed and permeabilized as described above and stained intracellularly with Foxp3-Alexa Fluor 488 (eBiosciences) for 30 min. .. Generation of matrix protein 1-expressing A549 cells and detection of MP158-66 –specific CD8+ T cells Shorter version of M1 gene (M1v1–699 bp) was obtained by PCR from a plasmid pCMV-H7N9-AH-13-M1 (Sino Biologicals Inc.) bearing a coding sequence (756 bp) for full-length matrix protein 1 (MP1) from H7N9 virus. .. M1v1 sequence was inserted into pcDNA-YFP plasmid (Invitrogen) to obtain pcDNA3-M1v1-YFP.

    Amplification:

    Article Title: Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
    Article Snippet: The cOVA coding sequence was amplified by PCR from the vector pCI-neo-cOVA , (a gift from Maria Castro, University of California, Los Angeles; Addgene plasmid no. 25097), and was cloned into pcDNA3, pTK126, or pSFV1-JC1 using the In-Fusion cloning kit according to the manufacturer’s instructions. .. The influenza HA coding sequence was amplified from the commercially available expression-ready influenza A H1N1 (A/WSN/33) cDNA clone, codon-optimized, full-length ORF (product no. VG11692-C; Sino Biological). .. EBOV GP coding sequences were amplified from pWRG7077-GP.

    Expressing:

    Article Title: Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
    Article Snippet: The cOVA coding sequence was amplified by PCR from the vector pCI-neo-cOVA , (a gift from Maria Castro, University of California, Los Angeles; Addgene plasmid no. 25097), and was cloned into pcDNA3, pTK126, or pSFV1-JC1 using the In-Fusion cloning kit according to the manufacturer’s instructions. .. The influenza HA coding sequence was amplified from the commercially available expression-ready influenza A H1N1 (A/WSN/33) cDNA clone, codon-optimized, full-length ORF (product no. VG11692-C; Sino Biological). .. EBOV GP coding sequences were amplified from pWRG7077-GP.

    Recombinant:

    Article Title: Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Article Snippet: .. In this study surface coated poly-(ɛ-caprolactone) (PCL) nanoparticles with chitosan (CS) were developed as a carrier system for nasal immunization using recombinant Influenza A virus (A/California/07/2009) H1N1 hemagglutinin (HA) protein, for the induction of humoral, cellular and mucosal immunity. ..

    Polymerase Chain Reaction:

    Article Title: Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
    Article Snippet: Cells were then fixed and permeabilized as described above and stained intracellularly with Foxp3-Alexa Fluor 488 (eBiosciences) for 30 min. .. Generation of matrix protein 1-expressing A549 cells and detection of MP158-66 –specific CD8+ T cells Shorter version of M1 gene (M1v1–699 bp) was obtained by PCR from a plasmid pCMV-H7N9-AH-13-M1 (Sino Biologicals Inc.) bearing a coding sequence (756 bp) for full-length matrix protein 1 (MP1) from H7N9 virus. .. M1v1 sequence was inserted into pcDNA-YFP plasmid (Invitrogen) to obtain pcDNA3-M1v1-YFP.

    Plasmid Preparation:

    Article Title: Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
    Article Snippet: Cells were then fixed and permeabilized as described above and stained intracellularly with Foxp3-Alexa Fluor 488 (eBiosciences) for 30 min. .. Generation of matrix protein 1-expressing A549 cells and detection of MP158-66 –specific CD8+ T cells Shorter version of M1 gene (M1v1–699 bp) was obtained by PCR from a plasmid pCMV-H7N9-AH-13-M1 (Sino Biologicals Inc.) bearing a coding sequence (756 bp) for full-length matrix protein 1 (MP1) from H7N9 virus. .. M1v1 sequence was inserted into pcDNA-YFP plasmid (Invitrogen) to obtain pcDNA3-M1v1-YFP.

    Sample Prep:

    Article Title: Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
    Article Snippet: Micro-crystalline tyrosine (MCT) was manufactured at Allergy Therapeutics Ltd, Worthing, UK, as a 4% w /v suspension in buffered saline, pH 6, containing 0.5% w /v phenol and was mixed 1.05:1 by volume with vaccine (2% target concentration). .. Sample preparation; MCT adsorption capacity 300 μl of 100 μg/ml H1N1 antigen (Influenza A H1N1 (A/Puerto Rico/8/1934), Haemagglutinin from SinoBiologicals Inc. was mixed with 700 μl of 2%w /v tyrosine blank (MCT) for 1 h at room temperature, to give a target H1N1 concentration of 30 μg/mL, followed by centrifugation of the sample for 4 min at 3 x g. An identical process was followed to produce the two controls, one control (control A) comprised antigen +DPBS and a second control (Control B) contained MCT alone. ..

    Adsorption:

    Article Title: Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
    Article Snippet: Micro-crystalline tyrosine (MCT) was manufactured at Allergy Therapeutics Ltd, Worthing, UK, as a 4% w /v suspension in buffered saline, pH 6, containing 0.5% w /v phenol and was mixed 1.05:1 by volume with vaccine (2% target concentration). .. Sample preparation; MCT adsorption capacity 300 μl of 100 μg/ml H1N1 antigen (Influenza A H1N1 (A/Puerto Rico/8/1934), Haemagglutinin from SinoBiologicals Inc. was mixed with 700 μl of 2%w /v tyrosine blank (MCT) for 1 h at room temperature, to give a target H1N1 concentration of 30 μg/mL, followed by centrifugation of the sample for 4 min at 3 x g. An identical process was followed to produce the two controls, one control (control A) comprised antigen +DPBS and a second control (Control B) contained MCT alone. ..

    Concentration Assay:

    Article Title: Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
    Article Snippet: Micro-crystalline tyrosine (MCT) was manufactured at Allergy Therapeutics Ltd, Worthing, UK, as a 4% w /v suspension in buffered saline, pH 6, containing 0.5% w /v phenol and was mixed 1.05:1 by volume with vaccine (2% target concentration). .. Sample preparation; MCT adsorption capacity 300 μl of 100 μg/ml H1N1 antigen (Influenza A H1N1 (A/Puerto Rico/8/1934), Haemagglutinin from SinoBiologicals Inc. was mixed with 700 μl of 2%w /v tyrosine blank (MCT) for 1 h at room temperature, to give a target H1N1 concentration of 30 μg/mL, followed by centrifugation of the sample for 4 min at 3 x g. An identical process was followed to produce the two controls, one control (control A) comprised antigen +DPBS and a second control (Control B) contained MCT alone. ..

    Centrifugation:

    Article Title: Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
    Article Snippet: Micro-crystalline tyrosine (MCT) was manufactured at Allergy Therapeutics Ltd, Worthing, UK, as a 4% w /v suspension in buffered saline, pH 6, containing 0.5% w /v phenol and was mixed 1.05:1 by volume with vaccine (2% target concentration). .. Sample preparation; MCT adsorption capacity 300 μl of 100 μg/ml H1N1 antigen (Influenza A H1N1 (A/Puerto Rico/8/1934), Haemagglutinin from SinoBiologicals Inc. was mixed with 700 μl of 2%w /v tyrosine blank (MCT) for 1 h at room temperature, to give a target H1N1 concentration of 30 μg/mL, followed by centrifugation of the sample for 4 min at 3 x g. An identical process was followed to produce the two controls, one control (control A) comprised antigen +DPBS and a second control (Control B) contained MCT alone. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections
    Article Snippet: Detection of Mouse Anti-Influenza mAbs C179, S139/1, and 9H10 For co-expression studies, to discriminate the expression of S139/1 and 9H10, both recognizing H3 epitopes, S139/1 was detected using the HA1 subunit and 9H10 was detected with H10N8. .. ELISA plates coated with 200 ng of H1N1 (A/WSN/33) HA, 50 ng of H3N2 (A/Aichi/2/1968) HA1 or HA subunit, or 200 ng of H10N8 (A/Jiangxi-Donghu/346/2013) HA (Sino Biologicals, Beijing, China) were blocked and incubated with serially diluted mouse serum. ..

    Article Title: Androgen supplementation improves some but not all aspects of immune senescence in aged male macaques
    Article Snippet: .. Plasma IgG antibody titers were measured on the day of vaccination and then on days 7, 14, and 28 or 35 (for MVA and H1N1 respectively) by enzyme-linked immunosorbent assay (ELISA) using plates coated with modified vaccinia virus (MVA) lysate (1 μg/mL) or with Influenza A (H1N1) 2009 Monovalent Vaccine overnight at 4 °C (0.15 μg HA antigen/mL Sino Biological, Inc., Beijing, China). .. Plates were then incubated with heat-inactivated (56 °C, 30 min) plasma samples in threefold dilution in triplicates.

    Incubation:

    Article Title: In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections
    Article Snippet: Detection of Mouse Anti-Influenza mAbs C179, S139/1, and 9H10 For co-expression studies, to discriminate the expression of S139/1 and 9H10, both recognizing H3 epitopes, S139/1 was detected using the HA1 subunit and 9H10 was detected with H10N8. .. ELISA plates coated with 200 ng of H1N1 (A/WSN/33) HA, 50 ng of H3N2 (A/Aichi/2/1968) HA1 or HA subunit, or 200 ng of H10N8 (A/Jiangxi-Donghu/346/2013) HA (Sino Biologicals, Beijing, China) were blocked and incubated with serially diluted mouse serum. ..

    Modification:

    Article Title: Androgen supplementation improves some but not all aspects of immune senescence in aged male macaques
    Article Snippet: .. Plasma IgG antibody titers were measured on the day of vaccination and then on days 7, 14, and 28 or 35 (for MVA and H1N1 respectively) by enzyme-linked immunosorbent assay (ELISA) using plates coated with modified vaccinia virus (MVA) lysate (1 μg/mL) or with Influenza A (H1N1) 2009 Monovalent Vaccine overnight at 4 °C (0.15 μg HA antigen/mL Sino Biological, Inc., Beijing, China). .. Plates were then incubated with heat-inactivated (56 °C, 30 min) plasma samples in threefold dilution in triplicates.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Sino Biological pbs
    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix <t>H1N1</t> antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP <t>(PBS)</t> than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).
    Pbs, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbs/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pbs - by Bioz Stars, 2021-07
    90/100 stars
      Buy from Supplier

    93
    Sino Biological recombinant nrp 1 pbs solution
    Ago2 and miR-21a-3p levels in TECs with or without <t>Nrp-1</t> knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Recombinant Nrp 1 Pbs Solution, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant nrp 1 pbs solution/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant nrp 1 pbs solution - by Bioz Stars, 2021-07
    93/100 stars
      Buy from Supplier

    99
    Sino Biological sars cov 2 2019 ncov spike s1 antibody rabbit mab
    <t>SARS-CoV-2</t> viruses with spike deletions transmit between humans. Maximum likelihood phylogenetic trees are rooted on MN985325 and were calculated with 10,000 (A and B) or 1000 (C) bootstrap replicates. Branches with transmitted RDR variants are colored red and detailed below. Patient data differentiating individual patients is provided. For clarity, bootstrap values below 70 are removed. Supporting figure S2 provides all branch labels. A. Transmission of an RDR2 variant among 4 individuals in Senegal (deletion positions 21,991-21,994). B. Transmission cluster of an RDR3 variant (deletion positions 22,189-22,192) among four Irish patients. C. Transmission of an RDR4 variant (deletion positions 22,281-22,290) among at least one male and female in Switzerland. D. Frequency of RDR variants among all complete genomes deposited in GISAID between December <t>2019</t> and October 24, 2020. E. Frequency of specific RDR deletion variants (numbered according to spike amino acids) among all GISAID variants over the same time period. The plot of RDR3/Δ210 has been adjusted by 0.02 units on the Y-axis for visualization in panel D due to its overlap with RDR2 and this adjustment has been retained in panel E to make direct comparisons between panels.
    Sars Cov 2 2019 Ncov Spike S1 Antibody Rabbit Mab, supplied by Sino Biological, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike s1 antibody rabbit mab/product/Sino Biological
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike s1 antibody rabbit mab - by Bioz Stars, 2021-07
    99/100 stars
      Buy from Supplier

    Image Search Results


    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Journal: PLoS ONE

    Article Title: Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

    doi: 10.1371/journal.pone.0114361

    Figure Lengend Snippet: Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Article Snippet: EIA for antibodies to recombinant H1N1 viral proteins Polystyrene plates were coated with recombinant HA from H1N1 influenza A/California/07/2009 vaccine strain or NP from A/Puerto Rico/8/1934 (H1N1) in PBS (both from Sino Biological, China), 0.1 µg/well.

    Techniques: Recombinant, Enzyme-linked Immunosorbent Assay

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Article Snippet: For recombinant Nrp-1 (Abcam), the equimolar biotinylated oligonucleotides were added into the recombinant Nrp-1 PBS solution with or without recombinant Ago2 (SinoBiological) at the equimolar concentration.

    Techniques: Western Blot, Quantitative RT-PCR

    Nrp-1 expression and distribution of TECs in different groups. (a) Representative Western Blot results of Nrp-1 in TECs of either control or sepsis (12 h: 12 hours after CLP) rat model). (b) Quantitative analysis of RT-PCR results of Nrp-1 mRNA transcription level in TECs of either control or sepsis (12 h: 12 hours after CLP) rat model). (c) Representative fluorescent results of Nrp-1 expression and distribution of TECs treated with different plasma. (d) Quantitative analysis of fluorescent results of Nrp-1 expression. (e) Quantitative analysis of RT-PCR results of Nrp-1 mRNA transcription level in TECs treated with different plasma. (f) Representative flow cytometry results of membrane Nrp-1 on TECs treated with different plasma. (g) Quantitative analysis of flow cytometry results of membrane Nrp-1 on TECs treated with different plasma. (h) Representative Western Blot results of membrane Nrp-1 on TECs treated with different plasma ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Nrp-1 expression and distribution of TECs in different groups. (a) Representative Western Blot results of Nrp-1 in TECs of either control or sepsis (12 h: 12 hours after CLP) rat model). (b) Quantitative analysis of RT-PCR results of Nrp-1 mRNA transcription level in TECs of either control or sepsis (12 h: 12 hours after CLP) rat model). (c) Representative fluorescent results of Nrp-1 expression and distribution of TECs treated with different plasma. (d) Quantitative analysis of fluorescent results of Nrp-1 expression. (e) Quantitative analysis of RT-PCR results of Nrp-1 mRNA transcription level in TECs treated with different plasma. (f) Representative flow cytometry results of membrane Nrp-1 on TECs treated with different plasma. (g) Quantitative analysis of flow cytometry results of membrane Nrp-1 on TECs treated with different plasma. (h) Representative Western Blot results of membrane Nrp-1 on TECs treated with different plasma ( ∗ P

    Article Snippet: For recombinant Nrp-1 (Abcam), the equimolar biotinylated oligonucleotides were added into the recombinant Nrp-1 PBS solution with or without recombinant Ago2 (SinoBiological) at the equimolar concentration.

    Techniques: Expressing, Western Blot, Quantitative RT-PCR, Flow Cytometry

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Article Snippet: For recombinant Nrp-1 (Abcam), the equimolar biotinylated oligonucleotides were added into the recombinant Nrp-1 PBS solution with or without recombinant Ago2 (SinoBiological) at the equimolar concentration.

    Techniques: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    SARS-CoV-2 viruses with spike deletions transmit between humans. Maximum likelihood phylogenetic trees are rooted on MN985325 and were calculated with 10,000 (A and B) or 1000 (C) bootstrap replicates. Branches with transmitted RDR variants are colored red and detailed below. Patient data differentiating individual patients is provided. For clarity, bootstrap values below 70 are removed. Supporting figure S2 provides all branch labels. A. Transmission of an RDR2 variant among 4 individuals in Senegal (deletion positions 21,991-21,994). B. Transmission cluster of an RDR3 variant (deletion positions 22,189-22,192) among four Irish patients. C. Transmission of an RDR4 variant (deletion positions 22,281-22,290) among at least one male and female in Switzerland. D. Frequency of RDR variants among all complete genomes deposited in GISAID between December 2019 and October 24, 2020. E. Frequency of specific RDR deletion variants (numbered according to spike amino acids) among all GISAID variants over the same time period. The plot of RDR3/Δ210 has been adjusted by 0.02 units on the Y-axis for visualization in panel D due to its overlap with RDR2 and this adjustment has been retained in panel E to make direct comparisons between panels.

    Journal: bioRxiv

    Article Title: Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

    doi: 10.1101/2020.11.19.389916

    Figure Lengend Snippet: SARS-CoV-2 viruses with spike deletions transmit between humans. Maximum likelihood phylogenetic trees are rooted on MN985325 and were calculated with 10,000 (A and B) or 1000 (C) bootstrap replicates. Branches with transmitted RDR variants are colored red and detailed below. Patient data differentiating individual patients is provided. For clarity, bootstrap values below 70 are removed. Supporting figure S2 provides all branch labels. A. Transmission of an RDR2 variant among 4 individuals in Senegal (deletion positions 21,991-21,994). B. Transmission cluster of an RDR3 variant (deletion positions 22,189-22,192) among four Irish patients. C. Transmission of an RDR4 variant (deletion positions 22,281-22,290) among at least one male and female in Switzerland. D. Frequency of RDR variants among all complete genomes deposited in GISAID between December 2019 and October 24, 2020. E. Frequency of specific RDR deletion variants (numbered according to spike amino acids) among all GISAID variants over the same time period. The plot of RDR3/Δ210 has been adjusted by 0.02 units on the Y-axis for visualization in panel D due to its overlap with RDR2 and this adjustment has been retained in panel E to make direct comparisons between panels.

    Article Snippet: Primary antibodies [rabbit anti-SARS-CoV-2 S monoclonal antibody, 40150-R007, Sino Biological, 1/700 dilution and human 4A8 monoclonal antibody, 1 μg/ml, in PBS containing 0.1 % (v/v) Triton X-100] were added and incubated at 37° Celsius for 1 hour.

    Techniques: Transmission Assay, Variant Assay

    Identification and characterization of recurrent deletion regions in SARS-CoV-2 spike protein. A. The number of deletion events identified among sequences in the GISAID SARS-CoV-2 sequence database mapped to the S gene. These form four clusters, termed recurrent deletion regions (RDRs). B. Length distribution of deletion events shows a preference for deletions that preserve the reading frame. C. The percentage of deletion events at the indicated site that either maintain the open reading frame or introduce a frameshift or premature stop codon (F.S./Stop). D. Abundance of nucleotide deletions in each RDR. Positions are defined by reference sequence MN985325. E and F. Geographic (E) and genetic (F) distributions of RDR variants compared to the entire GISAID database (sequences from 12-1-2019 to 10-24-2020). GISAID clade classifications are used in F.

    Journal: bioRxiv

    Article Title: Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

    doi: 10.1101/2020.11.19.389916

    Figure Lengend Snippet: Identification and characterization of recurrent deletion regions in SARS-CoV-2 spike protein. A. The number of deletion events identified among sequences in the GISAID SARS-CoV-2 sequence database mapped to the S gene. These form four clusters, termed recurrent deletion regions (RDRs). B. Length distribution of deletion events shows a preference for deletions that preserve the reading frame. C. The percentage of deletion events at the indicated site that either maintain the open reading frame or introduce a frameshift or premature stop codon (F.S./Stop). D. Abundance of nucleotide deletions in each RDR. Positions are defined by reference sequence MN985325. E and F. Geographic (E) and genetic (F) distributions of RDR variants compared to the entire GISAID database (sequences from 12-1-2019 to 10-24-2020). GISAID clade classifications are used in F.

    Article Snippet: Primary antibodies [rabbit anti-SARS-CoV-2 S monoclonal antibody, 40150-R007, Sino Biological, 1/700 dilution and human 4A8 monoclonal antibody, 1 μg/ml, in PBS containing 0.1 % (v/v) Triton X-100] were added and incubated at 37° Celsius for 1 hour.

    Techniques: Sequencing, Introduce